Adaptive Biotechnologies Corporation (ADPT)
ADPTNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$29.36
-0.9000 (-2.97%) today
At the close, Nov 10, 4:00 PM ET. After hours $29.36 –
- Market cap
- $4.75bn
- P/E
- –
- EPS, last 4 quarters
- $-0.3000
- Dividend yield
- –
- Day range
- $28.95 to $30.81
- 52-week range
- $12.00 to $30.79
- Average volume
- 2.23m
- Previous close
- $30.26
Analysts
8 coveringBuy7 buy, 1 hold, 0 sell
Targets a year out average $33.43, +13.9% from here
Earnings
next estimate $-0.0500Next report
Dec 2025
+52.6%
Mar 2026
+18.8%
Jun 2026
+23.1%
Sep 2026
+120.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $71.68m | $70.87m | $71.55m | $83.90m |
| Gross profit | $53.46m | $52.17m | $51.39m | $63.97m |
| Operating income | -$12.77m | -$19.21m | -$15.77m | -$457.0k |
| Net income | -$13.58m | -$20.03m | -$39.79m | $2.88m |
Last four quarters: revenue $298.01m, margin -23.7%, free cash flow -$8.82m
News
8 latest- Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?Zacks · 7 hours ago
- Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?Zacks · 8 hours ago
- Adaptive (ADPT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Adaptive Biotechnologies Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top EstimatesZacks · 6 days ago
- Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · 6 days ago
- Adaptive Biotechnologies Consensus Price Target Increased by 11.11% to $28.05Fintel · Oct 2, 2026
- Adaptive Biotechnologies Spotlights MRD Testing In Myeloma Cure Criteria RTTNews · Sep 25, 2026
The company
Adaptive Biotechnologies ('we' or 'our') is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- adaptivebiotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.